ZEALAND PHARMA A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 595 DKK | -0.58% |
|
-0.25% | +59.70% |
| Apr. 04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| Mar. 20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
598.5
DKK
Average target price
754.3
DKK
Spread / Average Target
+26.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +59.70% | 5.31B | |
| -3.39% | 102B | |
| +2.61% | 96.84B | |
| -0.87% | 21.48B | |
| -18.14% | 20.82B | |
| -7.33% | 18.6B | |
| -40.70% | 16.81B | |
| -26.89% | 13.78B | |
| +1.12% | 13.4B | |
| +22.25% | 11.06B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma A/S : European ADRs Move Higher in Tuesday Trading
